Author ORCID Identifier

0000-0001-7727-0875

Date of Graduation

5-2023

Document Type

Dissertation (PhD)

Program Affiliation

Immunology

Degree Name

Doctor of Philosophy (PhD)

Advisor/Committee Chair

Katayoun Rezvani

Committee Member

Michael A. Curran

Committee Member

Ken Chen

Committee Member

Vahid Afshar-Kharghan

Committee Member

Yair Reisner

Committee Member

Navin Varadarajan

Committee Member

Michael R. Green

Abstract

Trogocytosis is an active process that transfers surface material from targeted to effector cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen receptor (CAR) activation in natural killer (NK) cells promoted the transfer of the CAR-cognate-antigen from tumor to NK cells, resulting in (1) lower tumor antigen density, thus impairing the ability of CAR-NK cells to engage with their targets, (2) induced self-recognition and continuous CAR-mediated engagement, resulting in fratricide of trogocytic antigen expressing NK cells (NKTROG+) and NK cell hyporesponsiveness. This phenomenon could be offset by a dual-CAR system incorporating both an activating CAR (aCAR) against the cognate tumor antigen and an NK self-recognizing inhibitory CAR (iCAR) that transferred a “don't kill me” signal to NK cells upon engagement with their TROG+ siblings. This system prevented trogocytic antigen-mediated fratricide, while sparing aCAR-signaling against the tumor antigen, and resulted in enhanced CAR-NK cell activity.

Comments

This has also been published in professional journal, citation as following:

Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29. Erratum in: Nat Med. 2024 Mar;30(3):906. doi: 10.1038/s41591-023-02770-1. PMID: 36175679; PMCID: PMC9942695.

Keywords

chimeric antigen receptor, NK cell, cellular engineering, trogocytosis, anti-tumor therapy, immunotherapy

Share

COinS